Movement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts

Market Focus09:32

On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.

The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.

Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120647811?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 09:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120647811","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts","media":"Market Focus","content":"<p><p>On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.</p><p>The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.</p><p>Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI BIO Rises 4.75% in Regular Trading, CXO Sector Momentum Continues Amid Acquisition and Earnings Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-10 09:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.</p><p>The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.</p><p>Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1120647811","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120647811","pubTimestamp":1786325571,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.The rally extends gains following the company's announcement on August 7 of a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"走势提醒|药明生物常规交易上涨4.75%，CXO板块在收购和盈利催化剂下势头持续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On August 10, WUXI BIO rose 4.75% in regular trading, trading at HK$47.34/share, with turnover of HK$217 million.The rally extends gains following the company's announcement on August 7 of a definitive agreement to acquire Transcenta Therapeutics' process development and production base in Hangzhou, China. The facility is expected to enhance WUXI BIO's integrated end-to-end service capabilities covering drug substance development, production, and drug product manufacturing, with the transaction anticipated to close in Q3. CEO Dr. Zhisheng Chen stated the acquisition further strengthens the company's comprehensive service offering.Additionally, the broader CXO sector continues to trade strongly after peer WuXi AppTec reported robust first-half results, with revenue of RMB 28.9 billion (+38.93% YoY) and adjusted net profit surging 89.39% YoY. Market participants also maintain positive expectations ahead of WUXI BIO's board meeting scheduled for August 25 to review interim results. Within the Life Sciences Tools and Services sector, WUXI APPTEC rose 4.52%, XTALPI rose 8.41%, INSILICO rose 7.35%, and GENSCRIPT BIO rose 2.7%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120647811","isCrawlerRequest":true}